Journal
NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms13501
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research (CIHR) Foundation [FDN-143204]
- Yale Diabetes Research Centre [P30 DK45735]
- CIHR
- Canadian Diabetes Association
- CIHR Doctoral Research Scholarship
- Ontario Graduate Scholarship
- Banting and Best Diabetes Centre Graduate Studentship
- CIHR Graduate Scholarship
Ask authors/readers for more resources
Impaired glucose homeostasis and energy balance are integral to the pathophysiology of diabetes and obesity. Here we show that administration of a glycine transporter 1 (GlyT1) inhibitor, or molecular GlyT1 knockdown, in the dorsal vagal complex (DVC) suppresses glucose production, increases glucose tolerance and reduces food intake and body weight gain in healthy, obese and diabetic rats. These findings provide proof of concept that GlyT1 inhibition in the brain improves glucose and energy homeostasis. Considering the clinical safety and efficacy of GlyT1 inhibitors in raising glycine levels in clinical trials for schizophrenia, we propose that GlyT1 inhibitors have the potential to be repurposed as a treatment of both obesity and diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available